14956 Federal Register / Vol. 60, No. 54 / Tuesday, March 21, 1995 / Notices

deadline by which license applications

must be received.

SUPPLEMENTARY INFORMATION:

The National Institute of

Environmental Health Sciences has

developed procedures and a prototype

device for isolation of proteins from

complex mixtures for protein

sequencing. The system serves as a onestep purification method for isolation of

biologically relevant proteins affected

by disease or experimental treatment

and has been described in

Electrophoresis 15,535–545,1994. The

system includes a preparative isoelectric

focusing device for separation of

proteins by charge, a glass mold for

preparative polyacrylamide gel

separation by mass and a protocol for

use.

The commercial advantage of the

Preparative Two Dimensional Gel

Electrophoresis system is to separate

and isolate sufficient amounts of

individual protein for sequencing in a

powerful one-step purification method.

The Preparative Two Dimensional Gel

Electrophoresis system can resolve

individual proteins by charge and mass

from up to 1 to 2 mg of unpurified

starting material from protein mixtures.

Current devices for two dimensional gel

electrophoresis are generally for

analytical scale work and are not

physically or procedurally adapted to

accommodate preparative sample loads.

Although other preparative

electrophoresis devices do exist, they

separate by either mass or charge alone

and function as stand-alone units

without ready integration into

additional systems for resolution of

individual proteins.

The developed technology has

applications for protein sequencing,

protein immunization for antibody

production, immunostaining and other

modes of protein characterization.

Although the system has been tested

and is operational, some refinements in

protein resolution are still possible

which may involve procedural, reagent

or equipment modifications.

The CRADA awardees will have an

option to negotiate for an exclusive

license to market and commercialize

any new technology developed within

the scope of the CRADA research plan

for the Preparative Two Dimensional

Gel Electrophoresis System. This

CRADA may be directed toward the codevelopment of improved preparative

electrophoresis equipment and

pertinent procedures.

Roles of NIEHS

1. Provide design and specifications

of an operating prototype device,

provide a protocol for prototype

operation, provide user expertise, and

assist in beta testing.

2. Work cooperatively with the

company(s) to determine the market

potential for the Preparative Two

Dimensional Gel Electrophoresis system

and to refine the prototype system.

Roles of the CRADA Partner

1. Provide expertise in application

and commercial-oriented separation

systems.

2. Develop plan for production,

testing and commercialization of

Preparative Two Dimensional Gel

Electrophoresis system.

Selection criteria for choosing the

CRADA partner(s) will include, but will

not be limited to the following:

1. Experience in manufacturing

electrophoresis devices or related

separation technologies.

2. Capability to develop, implement

and manage the product

commercialization so as to ensure the

dissemination of the technology(s) to

research or health care services.

3. Ability to cost share for production

and testing of a preparative twodimensional gel electrophoresis device.

Dated: March 13, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 95–6854 Filed 3–20–95; 8:45 am]

BILLING CODE 4140–01–P

National Heart, Lung, and Blood

Institute; Meeting

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the

following Heart, Lung, and Blood

Special Emphasis Panel.

The meeting will be open to the

public to provide concept review of

proposed contract or grant solicitations.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

inform the Contact Person listed below

in advance of the meeting.

Name of Panel: NHLBI SEP on Blood

Diseases.

Dates of Meeting: April 27–28, 1995.

Time of Meeting: 9 a.m.

Place of Meeting: National Institutes of

Health, Natcher Building, Building 45, Lower

Level Room D, Bethesda, Maryland.

Agenda: The panel will review the current

status of research in the designated areas,

identify gaps and make recommendations

regarding opportunities and priorities for

future contract or grant solicitations.

Contact Person: Dr. Fann Harding, 7550

Wisconsin Avenue, Room 5A08, Bethesda,

Maryland 20892, (301) 496–1817.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health)

Dated: March 14, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

National Institutes of Health.

[FR Doc. 95–6851 Filed 3–20–95; 8:45 am]

BILLING CODE 4140–01–M

National Heart, Lung, and Blood

Institute; Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following Heart,

Lung, and Blood Special Emphasis

Panel (SEP) meetings:

Name of SEP: Response and Adaptation to

Exercise-Unit II (Telephone Conference Call).

Date: April 6, 1995.

Time: 1 p.m.

Place: 5333 Westbard Avenue, Room 552,

Bethesda, Maryland.

Contact Person: S. Charles Selden, Ph.D.,

5333 Westbard Avenue, Room 552, Bethesda,

Maryland 20892, (301) 594–7476.

Purpose/Agenda: To review and evaluate

grant applications.

Name of SEP: The Insulin in Resistance

Atherosclerosis Study (IRAS).

Date: April 18, 1995.

Time: 12:30 p.m.

Place: Crystal Gateway Marriott, Arlington,

Virginia.

Contact Person: David Monsees, Jr., Ph.D.,

5333 Westbard Avenue, Room 550, Bethesda,

Maryland 20892, (301) 594–7450.

Purpose/Agenda: To review and evaluate

grant applications.

These meetings will be closed in

accordance with the provisions set forth

in sec. 552b(c)(4) and 552b(c)(6), Title 5,

U.S.C. Applications and/or proposals

and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material

and personal information concerning

individuals associated with the

applications and/or proposals, the

disclosure of which would constitute a

clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.837, Heart and Vascular

Diseases Research; 93.838, Lung Diseases

Research; and 93.839, Blood Diseases and

Resources Research, National Institutes of

Health)

Dated: March 14, 1995.

Margery G. Grubb,

Senior Committee Management Specialist,

National Institutes of Health.

[FR Doc. 95–6850 Filed 3–20–95; 8:45 am]

BILLING CODE 4140–01–M